122 related articles for article (PubMed ID: 30865371)
21. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
[TBL] [Abstract][Full Text] [Related]
22. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
23. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
[TBL] [Abstract][Full Text] [Related]
24. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.
Czauderna P; Katski K; Kowalczyk J; Kurylak A; Lopatka B; Skotnicka-Klonowicz G; Sawicz-Birkowska K; Godziński J
Eur J Pediatr Surg; 2000 Oct; 10(5):300-3. PubMed ID: 11194540
[TBL] [Abstract][Full Text] [Related]
25. Coagulation disturbances in paediatric patients with hepatic veno-occlusive disease after stem cells transplantation.
Jevtić D; Vujić D; Zecević Z; Veljković D; Gazikalović S; Elezović I
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():33-8. PubMed ID: 20229680
[TBL] [Abstract][Full Text] [Related]
26. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
27. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Iguchi A; Kobayashi R; Kaneda M; Kobayashi K
Pediatr Blood Cancer; 2010 Mar; 54(3):437-43. PubMed ID: 19911420
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation.
Iguchi A; Kobayashi R; Yoshida M; Kobayashi K; Matsuo K; Kitajima I; Maruyama I
Bone Marrow Transplant; 2001 Jun; 27(11):1173-80. PubMed ID: 11551028
[TBL] [Abstract][Full Text] [Related]
29. [Hypercoagulability in patients with veno-occlusive disease after bone marrow transplantation].
Salat C; Holler E; Reinhardt B; Kolb HJ; Pihusch R; Neumeister P; Hiller E
Med Klin (Munich); 1994 May; 89(5):245-7. PubMed ID: 8052177
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine.
Lee AC; Aung L
Pediatr Blood Cancer; 2019 Feb; 66(2):e27518. PubMed ID: 30350914
[TBL] [Abstract][Full Text] [Related]
31. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
32. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
33. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
34. Wilms' tumor complicated by veno-occlusive disease of the liver (VOD): current concepts and a case report.
Nybonde T
Pediatr Hematol Oncol; 1989; 6(4):389-90. PubMed ID: 2561917
[No Abstract] [Full Text] [Related]
35. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation.
Pihusch V; Pihusch M; Penovici M; Kolb HJ; Hiller E; Pihusch R
Thromb Res; 2005; 116(3):233-40. PubMed ID: 15935832
[TBL] [Abstract][Full Text] [Related]
36. [Hepatic veno-occlusive disease--simulating acute abdomen in chemotherapy of Wilms' tumors].
Tröbs RB; Rothe K; Meier T
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():1112-4. PubMed ID: 9101794
[TBL] [Abstract][Full Text] [Related]
37. Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants.
Jevtic D; Zecevic Z; Veljkovic D; Dopsaj V; Radojicic Z; Elezovic I
J Pediatr Hematol Oncol; 2011 Apr; 33(3):227-34. PubMed ID: 21336167
[TBL] [Abstract][Full Text] [Related]
38. Hepatic veno-occlusive disease in Wilms' tumor.
Kullendorff CM; Békássy AN
Eur J Pediatr Surg; 1996 Dec; 6(6):338-40. PubMed ID: 9007466
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
[TBL] [Abstract][Full Text] [Related]
40. Veno-occlusive disease of the liver in right-sided Wilms' tumours.
Tornesello A; Piciacchia D; Mastrangelo S; Lasorella A; Mastrangelo R
Eur J Cancer; 1998 Jul; 34(8):1220-3. PubMed ID: 9849483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
